MCD-386CR (CDD-0102A) is a functionally selective agonist with partial agonist activity at M1 muscarinic receptors, weak activity at M3 receptors, and no activity at other muscarinic receptor subtypes. In preclinical studies, it enhances memory function in animal models of Alzheimer's disease. MCD-386CR (CDD-0102A) received orphan drug designation from FDA in 2011. The drug is intended to treat progressive supranuclear palsy, a degenerative brain disease that affects balance, walking, speech, cognition, and eye movements.